After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
ARQT belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Arcutis Biotherapeutics Inc is $1.09B. A total of 2.92 million shares were traded on the day, compared to an average of 4.62M shares.
In the most recent transaction, Heron Patrick J bought 21,052 shares of ARQT for 9.50 per share on Mar 04 ’24. After the transaction, the Director now owns 8,785,284 company shares. In a previous transaction on Mar 04 ’24, Watanabe Todd Franklin sold 14,903 shares at 11.12 per share. ARQT shares that the insider owns now total 874,533.
Among the insiders who sold shares, Burnett Patrick disposed of 4,782 shares on Mar 04 ’24 at a per-share price of $11.12. This resulted in the insider holding 269,300 shares of ARQT after the transaction. In another insider transaction, Matsuda Masaru sold 3,760 shares at $11.12 per share on Mar 04 ’24. Company shares held by the See Remark now total 190,424.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ARQT has a high of $15.21 and a low of $1.76.
As of this writing, ARQT has an earnings estimate of $Arcutis Biotherapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Arqit Quantum Inc. estimates, with a high estimate of $ARQL per share and a lower estimate of $Arcturus Therapeutics Holdings .
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $0.92, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.50.
